Previous 10 | Next 10 |
As the US Department of Health and Human Services notes, Alzheimer’s disease (AD) is a degenerative brain disorder that results in cognitive decline and basic thinking skills which slowly gets worse over time. According to a 2019 Alzheimer’s disease facts and figures re...
LAUSANNE, Switzerland, Sept. 04, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced The Michael J. Fox Foundation for Parkinson’s Research (MJFF) ha...
AC Immune ( ACIU ) Q2 results (CHF): Revenues: 1.5M (-25.0%). More news on: AC Immune SA, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
AC Immune (NASDAQ: ACIU ): Q2 GAAP EPS of -CHF0.24. More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more ...
LAUSANNE, Switzerland, Aug. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative diseases, today announced its business and clinical plan and strategy, reported consolidated finan...
AC Immune SA (NASDAQ: ACIU ) has announced a research partnership with leading scientists in the Perelman School of Medicine at the University of Pennsylvania (Penn) focused on studying the pathological mechanisms of TDP-43 misfolding and aggregation. More news on: AC Immune SA, Healthca...
LAUSANNE, Switzerland, Aug. 12, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced a research partnership with leading scientists in the Perelman School of...
AC Immune ( ACIU +2.1% ) initiates a Phase 1b/2a clinical trial evaluating ACI-35.030, an anti-phospho-Tau vaccine, in patients with early-stage Alzheimer's disease (AD). More news on: AC Immune SA, Healthcare stocks news, Stocks on the move, Read more ...
LAUSANNE, Switzerland, Aug. 01, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the initiation of a Phase 1b/2a clinical trial to evaluate ACI-35.030, a...
AC Immune SA (NASDAQ: ACIU ) has announced dosing of the first subject in a Phase 1 study of ACI-3024, an investigational oral small molecule Tau Morphomer inhibitor to address neurodegenerative diseases that are characterized by the presence of pathological Tau aggregates. More news on:...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...